Understand the source comparison
Best Peptides for Stroke Prevention: Clinical Comparison
This table compares the mechanisms, clinical evidence, and practical considerations for peptides with documented or theoretical stroke-prevention effects. Cerebrolysin Neurotrophic factor mimetic (BDNF, NGF pathways) 6 RCTs in acute stroke (modest benefit); ob
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the mechanisms, clinical evidence, and practical considerations for peptides with documented or theoretical stroke-prevention effects.
- Cerebrolysin
- Neurotrophic factor mimetic (BDNF, NGF pathways)
- 6 RCTs in acute stroke (modest benefit); observational data suggest 22% recurrence reduction
- 30–50ml IV infusion over 10–20 days
- High (low-molecular-weight peptides cross BBB)
- Strongest evidence base for post-stroke neuroprotection; prevention data is observational but mechanistically sound
- Thymalin
- Immune modulation (increases Treg cells, reduces IL-6/TNF-α)
- Reduces systemic inflammation markers by 30–35% in elderly cohorts; no dedicated stroke trial
- 10–20mg subcutaneous 2–3×/week
- Minimal (acts systemically, not CNS-direct)
- Indirect benefit through inflammation reduction; best suited for patients with elevated CRP or inflammatory biomarkers
- Dihexa
- HGF receptor agonist (increases synaptic density, dendritic branching)
- Phase I safety trial only (n=20); no stroke-specific outcomes
- 5mg oral daily (investigational)
- High (oral bioavailability ~50%)
- Compelling preclinical data; human stroke trials needed before clinical recommendation
- MK-677
- Growth hormone secretagogue (increases IGF-1 by 40–90%)
- No stroke trials; neuroprotective effects documented in IGF-1 research
- 10–25mg oral daily
- Moderate (IGF-1 crosses BBB via active transport)
- Theoretical benefit through IGF-1 neuroprotection; evidence base is extrapolated, not direct
- P21
- CNTF-derived peptide (ciliary neurotrophic factor pathway)
- Preclinical only; increases neurogenesis in rodent hippocampus
- 1–5mg subcutaneous 2×/week
- High (small peptide, crosses BBB)
- Early-stage research; mechanism is promising but human data doesn't exist yet